Endocrine最新文献

{"title":"Impact of health management on medication adherence and blood pressure and blood glucose indices in elderly patients with hypertension and diabetes mellitus.","authors":"Hong Yang, Junhua Hu, Ting Deng, Ting Li","doi":"10.1007/s12020-025-04249-0","DOIUrl":"10.1007/s12020-025-04249-0","url":null,"abstract":"<p><strong>Background: </strong>The occurrence of hypertension combined with diabetes can lead to a continuous deterioration in the physical condition of elderly patients. Health management, as an indispensable part of medical services, can achieve early prevention of diseases, early treatment of existing conditions, and the integration of prevention and treatment.</p><p><strong>Objective: </strong>We aimed to explore the impact of health management on blood pressure and blood glucose levels, health knowledge mastery, medication adherence, self-management abilities, and quality of life in elderly patients with hypertension (HTN) and diabetes mellitus (DM).</p><p><strong>Methods: </strong>One hundred and fifty elderly patients with HTN and DM who underwent physical examinations from January 2022 to December 2023 were enrolled. Those who received routine health management from January 2022 to December 2022 were assigned to the control group, while those who received comprehensive health management from January 2023 to December 2023 were assigned to the observation group, with 75 patients in each group. Key outcomes were compared, including lipid profiles, blood pressure, glycosylated hemoglobin, fasting plasma glucose, 2-hour postprandial blood glucose, the time taken for physical examinations, patient compliance rates, and physical examination accuracy rates, disease-related knowledge scores, self-management capacity through ESCA scale, quality of life through DSQL scale, and medication adherence through MMAS-8 scale.</p><p><strong>Results: </strong>The observation group demonstrated lower lipid levels, blood pressure, and glycemic indices, along with improved examination efficiency, higher disease knowledge scores, higher ESCA scale and MMAS-8 scale scores, and lower DSQL scale scores than the control group (P < 0.01).</p><p><strong>Conclusion: </strong>Providing health management to elderly patients with HTN and DM significantly reduced blood lipid, blood pressure, and blood glucose levels, improve patients' self-management ability, quality of life, and medication adherence, thereby contributing to disease management.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"448-455"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An evaluation of cases of disorders of sex development related to SRD5A2.","authors":"Can Celiloglu, Ihsan Turan, Leman Damla Kotan, Ayşe Merve Cimen, Semine Ozdemir Dilek, Bilgin Yuksel","doi":"10.1007/s12020-025-04252-5","DOIUrl":"10.1007/s12020-025-04252-5","url":null,"abstract":"<p><strong>Purpose: </strong>Pathogenic variants in SRD5A2 are a common cause of 46,XY disorders of sex development (DSDs). The aim of this study is to present the clinical, laboratory, and genetic characteristics of patients diagnosed with SRD5A2-associated 46,XY disorders of sex development (DSD), along with any decisions made regarding sex assignment. Furthermore, it also highlights the challenges encountered in sex assignment and the potential influence of social factors on how families adapt to these decisions.</p><p><strong>Methods: </strong>This retrospective, single-center study analyzed 29 DSD cases with 46,XY karyotypes, all of which were found to carry SRD5A2 variants.</p><p><strong>Results: </strong>The majority of the patients initially presented with female sex assignment (86.2%). The study identified a predominance of homozygous SRD5A2 variants (93.1%) with the most common variant being p.Ala65Pro. Gender assignment decisions were made for 25 cases, with male gender assignment in 80% of cases. The parents of three adolescent athlete patients did not comply with the male gender decision and one of these patients was supported as a girl after the age of 18, with a corrective operation being subsequently performed. No patients underwent a gonadectomy before the age of 18.</p><p><strong>Conclusion: </strong>This study emphasizes the challenges in sex assignment for SRD5A2-associated DSD. Some XY DSD patients may have difficulty adhering to medical team guidance because of the negative impact of the patients in their families. When necessary, gender assessment committees should reevaluate DSD cases from a current perspective and reconsider their decisions.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"632-640"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An in-depth exploration of the catecholamine and dyslipidemia relationship in pheochromocytoma and paraganglioma patients: a large Chinese cohort study.","authors":"Wenqian Zhang, Yue Zhou, Yunying Cui, Jie Yu, Tianyi Li, Kai Feng, Weidong Ren, Anli Tong, Yuxiu Li","doi":"10.1007/s12020-025-04277-w","DOIUrl":"10.1007/s12020-025-04277-w","url":null,"abstract":"<p><strong>Objective: </strong>The aim is to investigate the relationship between catecholamine levels and dyslipidemia in pheochromocytoma and paraganglioma (PPGL) patients.</p><p><strong>Methods: </strong>Clinical data from 500 PPGL patients were retrospectively analyzed, including clinical demographics, genetic mutations, tumor size, preoperative catecholamine levels, and lipid profiles. Comparison of lipid levels before and after surgery were also conducted.</p><p><strong>Results: </strong>A total of 500 patients were included: 238 males (47.6%) and 262 females (52.4%), with an average age at diagnosis of 46.5 ± 15.4 years. The prevalence of dyslipidemia among PPGL patients was 59.2%. In different catecholamine secretion types, norepinephrine (NE) secreting type group had significantly higher total cholesterol levels (4.82 [4.21, 5.38] vs. 4.43 [3.78, 4.92] mmol/L, p < 0.0167) compared to the non-secreting type group. However, there were no significant differences in triglycerides, high-density lipoprotein, and low-density lipoprotein among different secretion types. This study showed the first detailed analysis of the distribution of elevated total cholesterol in different age groups and BMI categories. Patients with overweight had the highest rate of elevated total cholesterol (48.5%). Additionally, within different age brackets, individuals aged 51-60 years displayed the highest rate of abnormal total cholesterol levels. Comparison of preoperative and postoperative biochemical outcomes in 69 patients with PPGLs showed that surgical resection effectively reduced catecholamine levels and improved total cholesterol levels.</p><p><strong>Conclusions: </strong>The incidence of dyslipidemia is high among patients with PPGL, and there exists strong link between lipid metabolism and catecholamine secretion, thus highlighting the importance of closely monitoring lipid levels in patients with PPGL.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"595-602"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare combination of hypogonadotropic hypogonadism, GH deficiency and rectal atresia in a female with an FGFR1 variant: a case report and systematic review of the literature.","authors":"Krystallenia I Alexandraki, Odysseas Violetis, Eleni Memi, Helen Fryssira, Vasileios Papanikolaou, Maria Papagianni, George Mastorakos","doi":"10.1007/s12020-025-04261-4","DOIUrl":"10.1007/s12020-025-04261-4","url":null,"abstract":"<p><strong>Purpose: </strong>To report a case with combined pituitary hormone deficiency (CPHD) and Fibroblast growth factor receptor 1 (FGFR1) gene defect, and summarize the clinical characteristics of similar cases by reviewing the current reports from the literature.</p><p><strong>Methods: </strong>A 24-year-old woman was admitted to the outpatient endocrinology unit with a diagnosis of primary amenorrhea, history of Growth Hormone deficiency and multiple congenital anomalies including rectal atresia. The subsequent hormonal investigation led to the diagnosis of hypogonadotropic hypogonadism and persistent GH deficiency. Abdominal and pelvic ultrasounds were normal whereas the brain MRI revealed a hypoplastic sella turcica with a hypoplastic anterior pituitary lobe, an ectopic posterior pituitary lobe and a thin pituitary stalk. The genetic analysis revealed a novel pathogenic missense heterozygous variant (c.1958G > A, p.Agr635Gln) in exon 15 of FGFR1 gene. PubMed, Scopus, and Web of Science were searched for the identification of studies reporting cases of CPHD with FGFR1 gene defects.</p><p><strong>Results: </strong>Of the 648 records retrieved, 10 were included in this review. A comprehensive overview of the cases was summarized, and their clinical and genetic characteristics were presented.</p><p><strong>Conclusion: </strong>Although FGFR1 variants have been associated with Kallmann syndrome and isolated hypogonadotropic hypogonadism and recently with CPHD, the patient's phenotype includes phenotypic alterations not previously described, to the best of our knowledge, within the spectrum of non-reproductive features of either of these entities. Isolated GH deficiency combined with other non-common abnormalities exerts a great possibility for subsequent CPHD manifestation.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"556-564"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144163090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary autoimmune hypothalamitis: management strategies and long-term outcomes in a tertiary care setting with a focused review of literature.","authors":"Liza Das, Ravi Shah, Rajender Kumar, Ritu Shree, Sushant Kumar Sahoo, Debajyoti Chatterjee, Chirag Kamal Ahuja, Paramjeet Singh, Bhagwant Rai Mittal, Manjul Tripathi, Pinaki Dutta","doi":"10.1007/s12020-025-04267-y","DOIUrl":"10.1007/s12020-025-04267-y","url":null,"abstract":"<p><strong>Background: </strong>Primary autoimmune hypothalamitis is an exceptionally rare inflammatory condition of the hypothalamus. Its etiology, clinical presentation, and management are not well established, with significant overlap and distinctions from hypophysitis.</p><p><strong>Material and methods: </strong>This study presents management and outcomes of patients with autoimmune hypothalamitis managed at a tertiary care centre. A literature review was also performed analyzing clinico-demographic, biochemical, radiological, and therapeutic characteristics.</p><p><strong>Results: </strong>There were 4 cases of autoimmune hypothalamitis out of 2200 sellar-suprasellar lesions managed over the past decade at our centre. Case 1 presented with arginine vasopressin (AVP) deficiency and adipsia, showing partial radiological response to glucocorticoids. Case 2 presented with neuropsychiatric features, with limited improvement on therapy. Case 3 had panhypopituitarism with stable disease on imaging, while Case 4 had AVP deficiency and hypogonadism with no significant radiological or hormonal recovery post therapy. Literature review (n = 34) of all cases showed female predominance (88%), but minimal association with pregnancy (6%). Polyuria-polydipsia was the most common presentation (81%), followed by memory disturbances and/or confusion (35%). Secondary hypogonadism was most common (88%) hormone deficiency followed by hypocortisolism (85%) and AVP deficiency (82%). T2 hyperintensity was the most common feature (95%) on MRI. Glucocorticoids enabled partial radiological response in most cases (82%), with hormonal recovery being less common (18%). Adjunctive medical therapy was required in 54.1% cases (most commonly azathioprine). Surgery was primarily used for biopsy and adjunctive radiotherapy in 3 cases. FDG-PET demonstrated utility in diagnosis, systemic involvement and follow-up.</p><p><strong>Conclusion: </strong>Autoimmune hypothalamitis remains a challenging diagnosis due to its rarity and overlapping features with other sellar pathologies. Histopathological evaluation or circulating antibodies can point towards the diagnosis. FDG-PET can be valuable in diagnosis and follow-up. Glucocorticoids are the mainstay of treatment, with partial radiological response commonly observed.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"532-546"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isovitexin, a natural adiponectin agonist, prevents glucocorticoid-induced osteosarcopenia.","authors":"Chirag Kulkarni, Saroj Kumar, Shamima Khatoon, Sreyanko Sadhukhan, Kaveri R Washimkar, Akhilesh Kumar, Shivani Sharma, Swati Rajput, Konica Porwal, Madhav Nilakanth Mugale, Srikanta Kumar Rath, Madan Madhav Godbole, Sabyasachi Sanyal, Navin Kumar, Ambrish Mithal, Naibedya Chattopadhyay","doi":"10.1007/s12020-025-04251-6","DOIUrl":"10.1007/s12020-025-04251-6","url":null,"abstract":"<p><strong>Purpose: </strong>Isovitexin is an agonist of adiponectin receptors (AdipoRs). Adiponectin has been shown to have beneficial effects on bone and muscle function, in addition to its positive impact on metabolic health. However, the preclinical and clinical application of adiponectin faces scalability challenges, prompting the investigation of isovitexin in a methylprednisolone (MP)-induced osteoporosis model.</p><p><strong>Methods: </strong>A rat model of MP-induced osteoporosis was developed to evaluate isovitexin's effects on bone health, including bone mass & microarchitecture (MicroCT), turnover markers (P1NP and CTX-1), strength (three-point bending, and nanoindentation), and quality (FTIR). We also investigated the muscle protective effects of isovitexin by measuring key muscle catabolic (atrogenes) proteins.</p><p><strong>Results: </strong>Isovitexin effectively prevented MP-induced osteopenia in critical weight-bearing, fracture-prone sites, such as the proximal femur and lumbar vertebrae. Bone turnover markers revealed its osteogenic and anti-resorptive properties, crucial for countering glucocorticoid-induced bone loss. Isovitexin treatment preserved the mineral and material composition of bone, indicating that it helps maintain the tissue integrity and mechanical strength. Hitherto observed effects of isovitexin likely resulted in the preservation of bone quality, demonstrated by preserving mechanical behavior and bone strength, which are essential for preventing fractures. MP treatment led to muscle atrophy, evidenced by reduced gastrocnemius diameter and cross-sectional area. Isovitexin countered these effects and inhibited atrogenes (atrogin-1 and MuRF-1) induction.</p><p><strong>Conclusion: </strong>Isovitexin not only mitigates osteopenia but also maintains overall bone quality and composition, exhibiting dual osteogenic and anti-resorptive effects. Its capacity to reduce muscle atrophy underscores its potential as a comprehensive treatment for glucocorticoid-induced osteoporosis and sarcopenia.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"565-577"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of glucose intolerance and risk factors in patients with gestational diabetes mellitus one year postpartum: a systematic review and meta-analysis.","authors":"Jie Liu, Leyang Liu, Xiaoqin Pang, Weiwei Liu","doi":"10.1007/s12020-025-04271-2","DOIUrl":"10.1007/s12020-025-04271-2","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;The purpose of this study is to explore the incidence and risk factors of glucose intolerance within one year postpartum in women with gestational diabetes mellitus (GDM), with the goal of informing the creation of effective preventive measures.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Method: &lt;/strong&gt;A systematic literature search was conducted in PubMed, Embase, Cochrane Library, Web of Science, Ovid, Scopus, CINAHL, Wiley, China National Knowledge Infrastructure Database (CNKI), WANFANG Database, China Science and Technology Journal Database (CSTJ), and China Biology Medicine Database (CBM) for records published from January 1990 to August 2024. The index terms included 'gestational diabetes mellitus', 'glucose intolerance', 'postpartum', and 'risk factor'. Investigators assessed eligibility, extracted data, and evaluated the methodological quality. The meta-analysis was conducted using Stata 17.0 and Review Manager 5.4.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Result: &lt;/strong&gt;Eighteen studies were included in the analysis, with 14 categorized as low risk of bias and 4 classified as medium risk of bias. The pooled incidence of glucose intolerance in women with GDM within 1 year postpartum was 34.5% (95% CI: 1.34-1.58). The following risk factors for glucose intolerance one year postpartum in women with GDM were identified: age (MD = 1.71; 95% CI: 0.50-2.91), pre-pregnancy BMI (MD = 1.75; 95% CI: 0.73-2.78), weight gain during pregnancy (MD = 1.25; 95% CI: 0.74-1.76), family history of diabetes (OR = 1.96; 95% CI: 1.58-2.42), fasting blood glucose at diagnosis (MD = 0.64; 95% CI: 0.39-0.88), 1-h postprandial blood glucose at diagnosis (MD = 1.24; 95% CI: 0.92-1.57), 2-h postprandial blood glucose at diagnosis (MD = 1.30; 95% CI: 0.72-1.87), history of GDM (OR = 2.62; 95% CI: 1.79-3.84), insulin use (OR = 2.41; 95% CI: 1.43-4.08), postpartum BMI (MD = 0.90; 95% CI: 0.24-1.55), diagnosed gestational weeks (MD = -1.82; 95% CI: -2.94--0.71), glycated hemoglobin (HbA1c) level at diagnosis (MD = 0.36; 95% CI: 0.14-0.58), HbA1c levels at 6-12 weeks postpartum (MD = 0.85; 95% CI: 0.42-1.29), fasting blood glucose levels 6 to 12 weeks postpartum (MD = 0.31; 95% CI: 0.05-0.57), 2-h postprandial blood glucose level 6 to 12 weeks postpartum(MD = 2.47; 95% CI: 0.68-4.26), Low-density lipoprotein (LDL) levels at diagnosis (MD = 0.20; 95% CI: 0.01-0.40), and triglyceride (TG) level at diagnosis(MD = 0.55; 95% CI: 0.34-0.75).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The incidence of glucose intolerance one year postpartum in women with GDM is relatively high. The subgroup analysis of this study revealed that the incidence is highest among Asian women and lowest among Caucasian women. 17 risk factors have been identified; these findings may help to better understand which GDM patients are more likely to experience glucose intolerance one year postpartum, and provide higher-level evidence for assessing the incidence and risk factors of glucose intolerance in GDM patients one year after deli","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"380-394"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of oral contraceptive use on muscle mass and strength in women with PCOS.","authors":"Seren Aksun, Levend Karaçoban, Ilkay Idilman, Bulent O Yildiz","doi":"10.1007/s12020-025-04305-9","DOIUrl":"10.1007/s12020-025-04305-9","url":null,"abstract":"<p><strong>Purpose: </strong>Polycystic ovary syndrome (PCOS) is characterized by androgen excess and ovulatory dysfunction and appears to be associated with alterations in muscle mass and function. The study aims to investigate whether oral contraceptive (OC) use affects muscle mass and strength in women with PCOS.</p><p><strong>Methods: </strong>Twenty women with PCOS (median age 20.5 years and BMI 26.1 kg/m²) and 20 age- and BMI-matched healthy controls were included. Clinical, hormonal, and biochemical assessments were conducted along with body composition analyses using magnetic resonance imaging (MRI) proton density fat fraction (PDFF%) and muscular strength assessment by isokinetic dynamometry. In women with PCOS, measurements were repeated after at least three cycles of OC therapy.</p><p><strong>Results: </strong>At baseline, women with PCOS exhibited significantly higher levels of total testosterone, free androgen index (FAI), and homeostasis model assessment of insulin resistance (HOMA-IR) levels compared to healthy controls (p < 0.001, p = 0.001, p = 0.004, respectively). PCOS group also showed significantly higher average power (AvP) of knee extensors at 60°/sec (p = 0.002). AvP correlated positively with total testosterone and FAI levels in the whole study group (r = 0.450, p = 0.004, r = 0.318, p = 0.045, respectively). Following OC therapy, testosterone levels and FAI decreased (p = 0.02 and p < 0.001, respectively); whereas thigh muscle mass or lower limb strength remained unchanged.</p><p><strong>Conclusions: </strong>Short-term OC use in women with PCOS led to a reduction in androgen excess without measurable effects on muscle composition or strength. These findings suggest that muscle function and composition remain stable over the short term, despite hormonal modulation. Further research is required to understand how long-term management strategies for PCOS might affect muscle mass and function.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"647-654"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of emerging RNA markers in thyroid fine needle aspiration cytology samples: advancements and challenges.","authors":"Gamze Sönmez, Uğur Ünlütürk","doi":"10.1007/s12020-025-04266-z","DOIUrl":"10.1007/s12020-025-04266-z","url":null,"abstract":"<p><strong>Background: </strong>Significant advances have been made in detecting RNA markers that may indicate malignancy in fine needle aspiration cytology (FNAC) samples.</p><p><strong>Objective: </strong>To review the roles of protein-coding and non-coding RNAs in differentiating between malignant and benign thyroid nodules.</p><p><strong>Methods: </strong>A comprehensive literature search using PubMed, Science Direct, Web of Science, and SCOPUS databases was performed. We searched up until September 2024 and complemented by manual citation search.</p><p><strong>Results: </strong>A total of 28 full-text articles were reviewed, encompassing 5770 FNAC samples, which included 3489 benign lesions and 2281 malignant lesions. The studies identified 43 messenger RNAs (mRNAs), 16 microRNAs (miRNAs), and 3 long non-coding RNAs (lncRNAs) that have the potential to distinguish malignant nodules. Among the mRNAs, PAPPA, TIMP1, and HMGA2, as well as the miRNAs, miR-146b, miR-375 and miR-222, appear to be the most promising molecules for diagnosis.</p><p><strong>Conclusion: </strong>Numerous RNA markers have been shown to differentiate malignant from benign lesions. However, there is still a lack of patient-specific classification for thyroid cancer subtypes. Additionally, future studies should prioritize using a combination of molecular markers rather than relying on individual ones. Although current research mainly focuses on identifying cancer-specific molecules, it is important for future studies to shift towards a more patient-specific approach.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"365-379"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of thyroglobulin changes on clinical outcomes of differentiated thyroid cancer with biochemical incomplete response.","authors":"Xiaohui Li, Tian Tian, Kexin Shi, Chenyu Sun, Rui Huang","doi":"10.1007/s12020-025-04247-2","DOIUrl":"10.1007/s12020-025-04247-2","url":null,"abstract":"<p><strong>Purpose: </strong>Partial patients with biochemical incomplete response (BIR) after initial therapy for differentiated thyroid cancer (DTC) may progress to structural recurrence during follow-up. For better-individualized care, this study analyzed predictors of structural recurrence in patients with BIR after initial radioactive iodine therapy (RAIT).</p><p><strong>Methods: </strong>A retrospective study was conducted on 4,263 patients with DTC who underwent thyroidectomy and initial RAIT between June 2009 and August 2023. Patients with either suppressed thyroglobulin (Sup-Tg) > 1 ng/mL or stimulated Tg (Sti-Tg) > 10 ng/mL and negative anti-Tg antibodies (TgAb < 40 IU/mL) without structural disease were enrolled. Pathological examination or imaging confirmed structural recurrence. Sup-Tg change level [ΔSup-Tg% = (Sup-Tg_3rd - Sup-Tg_2nd)/Sup-Tg_2nd × 100%] and other clinicopathological parameters were used to predict structural recurrence in patients with BIR.</p><p><strong>Results: </strong>We enrolled 161 patients with a median follow-up of 6.3 years. Fourteen patients (8.7%) progressed to structural disease, 80 (49.7%) remained in BIR status, and 67 (41.6%) recovered with long-term remission. ΔSup-Tg%≥17.08% displayed high specificity (84.4%) for structural recurrence prediction (AUC = 0.705, p = 0.011). Extrathyroid extension, stage III and ΔSup-Tg% were independent predictors of structural recurrence (OR = 4.568, p = 0.038; OR = 9.594, p = 0.015; and OR = 18.781, p < 0.001, respectively). Kaplan-Meier analysis showed that these factors were associated with structural recurrence-free survival. Cox regression analysis found that patients with stage III and ΔSup-Tg%≥17.08% have a higher risk of recurrence (HR = 4.818, p = 0.015 and HR = 10.173, p < 0.001, respectively).</p><p><strong>Conclusion: </strong>Longitudinal monitoring of Tg is essential and Tg change level could be used as a predictor of structural recurrence in patients with BIR.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"466-475"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}